國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Molecular determinants of head and n...

Burtness, Barbara.

Molecular determinants of head and neck cancer

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Molecular determinants of head and neck canceredited by Barbara Burtness, Erica A. Golemis.
其他作者:	Burtness, Barbara.
出版者:	Cham :Springer International Publishing :2018.
面頁冊數:	vi, 629 p. :digital ;24 cm.
Contained By:	Springer eBooks
標題:	HeadCancer
電子資源:	http://dx.doi.org/10.1007/978-3-319-78762-6
ISBN:	9783319787626$q(electronic bk.)

Molecular determinants of head and neck cancer
Molecular determinants of head and neck cancer[electronic resource] /edited by Barbara Burtness, Erica A. Golemis. - 2nd ed. - Cham :Springer International Publishing :2018. - vi, 629 p. :digital ;24 cm. - Current cancer research,2199-2584. - Current cancer research..

Squamous cell cancers of the head and neck (SCCHN), also known as head and neck cancers (HNC) encompass malignancies of the oral cavity, larynx, nasopharynx and pharynx, and are diagnosed in over 500,000 patients worldwide each year, accounting for 5% of all malignancies. It is estimated that approximately 50,000 patients develop head and neck cancer annually in the United States, of whom approximately 50% succumb to this cancer. For most cases of SCCHN, treatment is multimodal, often combining surgery or irradiation with chemotherapy; even successfully treated patients frequently experience durable and severe side effects. Improving cure rates and reducing chronic morbidity are urgent clinical needs for head and neck cancer. However, in contrast to cancer types such as breast or prostate that have been much studied and have well-defined biology, until recently, relatively few researchers investigated the molecular basis of HNC, making it difficult to design targeted treatments with better efficacy and less debilitating side effects. This volume will provide an overview of the factors contributing to disease pathogenesis, including the recognition of discrete molecular subtypes with distinct etiology, prognosis, and treatment response. This volume will familiarize the reader with the critical signaling pathways and oncogenic drivers for HNC. It will outline the differences between HPV-positive and HPV-negative disease, and how these differences affect treatment choice and outcome. The book will emphasize developments in the past five years, including the growing understanding of the genomic and epigenomic features of the disease based on analysis of next generation sequencing (NGS) data, and timely topics such as the analysis of HNC stem cell populations, non-coding mRNAs, and inflammatory response. It will address exciting new therapeutic approaches such as the use of immunotherapies to treat HNC patients. Overall, the book will provide the reader with current understanding of the biology and treatment of the disease, and describe timely questions that will guide future research aimed at controlling and curing this disease.

ISBN: 9783319787626$q(electronic bk.)

Standard No.: 10.1007/978-3-319-78762-6doiSubjects--Topical Terms:

458631
Head
--Cancer

LC Class. No.: RC280.H4 / M654 2018

Dewey Class. No.: 616.99491

Molecular determinants of head and neck cancer
LDR:03166nmm a2200325 a 4500 001 543198
003 DE-He213
005 20190131113236.0
006 m d
007 cr nn 008maaau
008 190411s2018 gw s 0 eng d
020 $a 9783319787626$q(electronic bk.)
020 $a 9783319787619$q(paper)
024 7 $a 10.1007/978-3-319-78762-6 $2 doi
035 $a 978-3-319-78762-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.H4 $b M654 2018
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99491 $2 23
090 $a RC280.H4 $b M718 2018
245 0 0 $a Molecular determinants of head and neck cancer $h [electronic resource] / $c edited by Barbara Burtness, Erica A. Golemis.
250 $a 2nd ed.
260 $a Cham : $b Springer International Publishing : $b Imprint: Humana Press, $c 2018.
300 $a vi, 629 p. : $b digital ; $c 24 cm.
490 1 $a Current cancer research, $x 2199-2584
520 $a Squamous cell cancers of the head and neck (SCCHN), also known as head and neck cancers (HNC) encompass malignancies of the oral cavity, larynx, nasopharynx and pharynx, and are diagnosed in over 500,000 patients worldwide each year, accounting for 5% of all malignancies. It is estimated that approximately 50,000 patients develop head and neck cancer annually in the United States, of whom approximately 50% succumb to this cancer. For most cases of SCCHN, treatment is multimodal, often combining surgery or irradiation with chemotherapy; even successfully treated patients frequently experience durable and severe side effects. Improving cure rates and reducing chronic morbidity are urgent clinical needs for head and neck cancer. However, in contrast to cancer types such as breast or prostate that have been much studied and have well-defined biology, until recently, relatively few researchers investigated the molecular basis of HNC, making it difficult to design targeted treatments with better efficacy and less debilitating side effects. This volume will provide an overview of the factors contributing to disease pathogenesis, including the recognition of discrete molecular subtypes with distinct etiology, prognosis, and treatment response. This volume will familiarize the reader with the critical signaling pathways and oncogenic drivers for HNC. It will outline the differences between HPV-positive and HPV-negative disease, and how these differences affect treatment choice and outcome. The book will emphasize developments in the past five years, including the growing understanding of the genomic and epigenomic features of the disease based on analysis of next generation sequencing (NGS) data, and timely topics such as the analysis of HNC stem cell populations, non-coding mRNAs, and inflammatory response. It will address exciting new therapeutic approaches such as the use of immunotherapies to treat HNC patients. Overall, the book will provide the reader with current understanding of the biology and treatment of the disease, and describe timely questions that will guide future research aimed at controlling and curing this disease.
650 0 $a Head $x Cancer $x Diagnosis. $3 458631
650 0 $a Neck $x Cancer $x Diagnosis. $3 458632
650 0 $a Head $x Cancer $x Treatment. $3 273850
650 0 $a Neck $x Cancer $x Treatment. $3 594738
650 1 4 $a Biomedicine. $3 273648
650 2 4 $a Cancer Research. $3 273660
650 2 4 $a Oncology. $3 195181
650 2 4 $a Protein Science. $3 376428
700 1 $a Burtness, Barbara. $3 680687
700 1 $a Golemis, Erica A. $3 680688
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Current cancer research. $3 558904
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-78762-6
950 $a Medicine (Springer-11650)